Marrow Therapeutics Overview
- Status
-
Private
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$120M
- Investors
-
11
Marrow Therapeutics General Information
Description
Developer of precision genetic medicines designed to treat severe blood disorders through targeted delivery. The company utilizes validated antibody-based therapeutics to specifically target cells affected by conditions like sickle cell disease and beta thalassemia early in their development, enabling the potential for functional cures without the need for traditional, invasive procedures.
Contact Information
Website
www.marrowtx.comCorporate Office
- 100 Forge Road
- Suite 200
- Watertown, MA 02472
- United States
Corporate Office
- 100 Forge Road
- Suite 200
- Watertown, MA 02472
- United States
Marrow Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 17-Nov-2026 | $120M | Completed | Clinical Trials - General | ||
| 2. Early Stage VC (Series A) | Completed | Clinical Trials - General | ||||
| 1. Seed Round | $2M | $2M | Completed | Clinical Trials - General |
Marrow Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A-1 | ||||||||
| Seed | 2,075,001 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 9.74% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Marrow Therapeutics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Affinity Asset Advisors | Hedge Fund | Minority | ||
| Columbia Threadneedle Investments | Asset Manager | Minority | ||
| Kohlberg Kravis Roberts | PE/Buyout | Minority | ||
| NextBio Capital | Venture Capital | Minority | ||
| Opaleye | Hedge Fund | Minority |
Marrow Therapeutics FAQs
-
Where is Marrow Therapeutics headquartered?
Marrow Therapeutics is headquartered in Watertown, MA.
-
What industry is Marrow Therapeutics in?
Marrow Therapeutics’s primary industry is Drug Discovery.
-
Is Marrow Therapeutics a private or public company?
Marrow Therapeutics is a Private company.
-
What is Marrow Therapeutics’s current revenue?
The current revenue for Marrow Therapeutics is .
-
How much funding has Marrow Therapeutics raised over time?
Marrow Therapeutics has raised $175M.
-
Who are Marrow Therapeutics’s investors?
Affinity Asset Advisors, Columbia Threadneedle Investments, Kohlberg Kravis Roberts, NextBio Capital, and Opaleye are 5 of 11 investors who have invested in Marrow Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process